<DOC>
	<DOC>NCT00474526</DOC>
	<brief_summary>This study will evaluate the safety and immune response of the Novartis Meningococcal ACWY conjugate vaccine when administered with routine infant vaccinations to healthy infants.</brief_summary>
	<brief_title>A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants</brief_title>
	<detailed_description />
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis, Meningococcal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Healthy term 2monthold infants for whom a parent/legal representative has given written informed consent. Subjects with a previous or suspected disease caused by Neisseria meningitidis, Corynebacterium diphtheriae, Clostridium tetani, Poliovirus, Hepatitis B, Haemophilus influenzae type b (Hib), Pneumococcus or Bordetella pertussis; previous immunization with a meningococcal vaccine or vaccine containing meningococcal antigen(s) or prior vaccination with Diptheria, Tetanus, Pertussis (acellular or whole cell), inactivated polio vaccineIPV or oral polio vaccineOPV, H. influenzae type b (Hib) or Pneumococcus; who have had household contact with and/or intimate exposure to an individual with laboratory confirmed N. meningitidis (serogroups A, C, W135, or Y), B. pertussis, Hib, C. diphtheriae, Polio, or pneumococcal infection at any time since birth; Any serious acute, chronic or progressive disease</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>2 Months</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Meningococcal</keyword>
	<keyword>meningitis</keyword>
	<keyword>vaccine</keyword>
	<keyword>infants</keyword>
	<keyword>Meningococcal meningitis</keyword>
	<keyword>Meningococcal disease</keyword>
</DOC>